Molecular Quantum Solutions Secures €600K Funding to Expedite R&D Simulations in Pharma, Biotech, and Chemical Industries

Share now

Read this article in:

Molecular Quantum Solutions Secures €600K Funding to Expedite R&D Simulations in Pharma, Biotech, and Chemical Industries
© Molecular Quantum Solutions

Denmark-based Molecular Quantum Solutions (MQS), a computational tools provider for accelerating R&D in the pharmaceutical, biotech, and chemical sectors, revealed on Thursday the successful completion of a pre-seed funding round, raising €600K.

Molecular Quantum Solutions has stated that it intends to utilize the raised funds to transform their developed tool stack into a Software-as-a-Service (SaaS) solution tailored for the pharmaceutical and chemical industries.

About the Investors

Scale Capital, along with Rockstart based in Amsterdam and Stokbro Invest, led the funding round.

Joachim Schelde, Investment Associate at Scale Capital, expresses his admiration for MQS’s product and commercial achievements, emphasizing their belief in the disruptive potential of MQS’s quantum chemistry simulation platform in the drug formulation domain.

Schelde adds, “We believe the company stands out from the competition and offers a compelling value proposition for accelerating the pharmaceutical R&D pipeline. We are thrilled to commence our collaboration!”

Michael Bjørnlund, Managing Partner of Rockstart Emerging Tech, highlights the significance of increasing computing power in addressing global challenges and emphasizes the value of expediting time to market to contribute to problem-solving on a global scale.

Bjørnlund states, “We invested in MQS to optimize computing power and drive advancements in Industry 4.0 and advanced analytics development. The MQS team demonstrates relentless dedication to building sophisticated quantum chemistry solutions in the domains of supercomputing and quantum computing, and we are excited to have joined them early on in their journey.”


About Molecular Quantum Solutions

Established in 2019 by Mark Nicholas Jones, Molecular Quantum Solutions specializes in delivering a software platform designed for computing the thermodynamic properties of molecules, catering specifically to the pharmaceutical and chemical sectors.

The company offers computational tools that assist pharmaceutical, biotech, and chemical companies in expediting their research and development endeavors.

Leveraging the power of supercomputers and quantum computing technology, their innovative solutions enable swift and efficient calculations of material and chemical characteristics through the utilization of computational models and algorithms.

In the phases of medication formulation and production upscaling, the pharmaceutical and biopharma industries typically invest a substantial amount ranging from $20 billion to $60 billion. With MQS, users can now test and analyze novel materials for various applications, including batteries, environmentally friendly solvents, medicinal pharmaceuticals, and biodegradable polymers. This eliminates the need for costly laboratory studies.

Mark Nicholas Jones, CEO/CTO of Molecular Quantum Solutions, states, “Over the past three years, we have established a robust infrastructure to perform computationally intensive quantum chemistry calculations in the cloud, addressing relevant industrial use cases.”

He further explains, “Moreover, we have developed pioneering quantum computing methods that we are integrating into our classical calculation pipeline. We have active collaborations with quantum computing research institutions and companies. Now, we are ready to expand into the global market with our suite of cloud-based products.”

About Rockstart

Rockstart is a visionary investor focused on supporting purpose-driven creators in the realms of energy, agribusiness, and emerging technologies.

Through fostering valuable connections between founders, co-investors, mentors, partners, corporations, and the extensive Rockstart network, the organization invests in early-stage entrepreneurs, providing them with crucial access to financing, market opportunities, and invaluable expertise.

With a track record of funding over 300 ventures, Rockstart’s portfolio companies collectively possess an estimated value of $1 billion. Comprised of a diverse group of over 45 international specialists, Rockstart collaborates closely to empower founders on their growth journey, promoting positive impact in the world.

In 2021, Rockstart witnessed successful exits of notable ventures such as Wercker, Bouw7, iClinic, and 3D Hubs.


Get the top Stories in your Inbox

Sign up for our Newsletters

Specials from our Partners